CHLOROQUINE PHOSPHATE

Search structure
Trade Names:
Synonyms:
Status: Approved (1949)
Entry Type: Small molecule
Molecule Category: Salt
UNII: 6E17K3343P
Parent Compound: CHLOROQUINE

Structure
InChI Key AEUAEICGCMSYCQ-UHFFFAOYSA-N
Smile CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=P(O)(O)O
InChI
InChI=1S/C18H26ClN3.H3O4P/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18;1-5(2,3)4/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21);(H3,1,2,3,4)

Physicochemical Descriptors

Property Name Value
Molecular Formula C18H32ClN3O8P2
Molecular Weight 515.87
AlogP 4.81
Hydrogen Bond Acceptor 3.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 8.0
Polar Surface Area 28.16
Molecular species BASE
Aromatic Rings 2.0
Heavy Atoms 22.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Ferriprotoporphyrin IX inhibitor PubMed
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Cytochrome P450 Cytochrome P450 family 2 Cytochrome P450 family 2D Cytochrome P450 2D6
- - - - 20
Enzyme Cytochrome P450 Cytochrome P450 family 3 Cytochrome P450 family 3A Cytochrome P450 3A4
- - - - 7
Enzyme Protease Metallo protease Metallo protease MAE clan Metallo protease M27 family
- - - - 7-7
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - - 84

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Arthritis, Rheumatoid 3 D001172 ClinicalTrials
Atrial Fibrillation 2 D001281 ClinicalTrials
Lupus Erythematosus, Systemic 2 D008180 ClinicalTrials
Severe Acute Respiratory Syndrome 2 D045169 ClinicalTrials
Pneumonia, Viral 2 D011024 ClinicalTrials
Severe Acute Respiratory Syndrome 2 D045169 ClinicalTrials
HIV Infections 2 D015658 ClinicalTrials

Related Entries

Scaffolds

Parent
Mixture

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Cardiac disorders
10.89
Nervous system disorders
10.42
Psychiatric disorders
10.15
Injury, poisoning and procedural complications
9.29
General disorders and administration site conditions
7.42
Investigations
6.91
Respiratory, thoracic and mediastinal disorders
5.89
Eye disorders
5.78
Musculoskeletal and connective tissue disorders
4.8
Vascular disorders
4.22
Metabolism and nutrition disorders
3.4
Gastrointestinal disorders
3.32
Blood and lymphatic system disorders
3.08
Immune system disorders
3.01
Skin and subcutaneous tissue disorders
2.93
Infections and infestations
2.89

Cross References

Resources Reference
ChEBI 3638
ChEMBL CHEMBL58510
EPA CompTox DTXSID7044681
FDA SRS 6E17K3343P
Guide to Pharmacology 5535
KEGG C07625
PDB CLQ
PubChem 64927
SureChEMBL SCHEMBL40827
ZINC ZINC01530861
CONTENTS